NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NAMSW Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of NAMSW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NAMSW's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to NAMSW
Recent picks made for NAMSW stock on CNBC
ETFs with the largest estimated holdings in NAMSW
Flights by private jets registered to NAMSW